PPARs are thought to play a key role in the pathology of NAFLD, and PPAR agonists are considered promising agents for the treatment of NAFLD (Boeckmans et al., 2019; Gawrieh et al., 2021). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.